Metformin mitigates gastrointestinal radiotoxicity and radiosensitises P53 mutation colorectal tumours via optimising autophagy

• DOI: 10.1111/bph.15149
• Publication Date: 2020-05-30T11:18:54Z
• Authors: Long Chen; Fengying Liao; Zhongyong Jiang; Chi Zhang; Ziwen Wang; Peng Luo; Qingzhi Jiang; Jie Wu; Qing Wang; Min Luo; Xueru Li; Yu Leng; Le Ma; Gufang Shen; Zelin Chen; Yu Wang; Xu Tan; Yibo Gan; Dengqun Liu; Yunsheng Liu; Chunmeng Shi
• Keywords: 0301 basic medicine; Mice; 0303 health sciences; 03 medical and health sciences; Mutation; Autophagy; Animals; Apoptosis; Tumor Suppressor Protein p53; Colorectal Neoplasms; Metformin; 3. Good health

There is an urgent but unmet need for mitigating radiation-induced intestinal toxicity while radio sensitising tumours abdominal radiotherapy. We aimed to investigate the effects of metformin on and radiosensitivity colorectal tumours.Acute chronic histological injuries intestine from mice were used assess radioprotection IEC-6 cell line was mechanisms in vitro. The fractionated radiation model HCT116 HT29 tumour grafts determine cancer.Metformin alleviated acute by optimising mitophagy which AMPK-dependent. In addition, our data indicated that increased with P53 mutation both vitro vivo.Metformin may be a radiotherapy adjuvant agent cancers especially those carrying mutation. Our findings provide new strategy further precise clinical trials